Igyxos’ IGX12 brings a fresh approach to infertility treatment, aiming to improve outcomes for both men and women.

Delve into Vandria's technology and its Alzheimer's candidate, VNA-318, the first mitophagy-based candidate in Alzheimer's in ...

A new wave of metabolic disease drugs beyond GLP-1 agonists is emerging to address the unmet needs of patients.

Discover the emergence of dual-payload ADCs and PDCs, which could mark a significant evolution in targeted therapeutics.

Discover six obesity deals made so far in 2025, with dealmaking activity in the field being largely dominated by big pharma companies.

While non-exhaustive, this list offers an overview of the year’s biotech events taking place around the world, aimed at partnering and connecting with decision makers in biopharma. If there is a ...

Recombinant protein expression lies at the heart of modern biotechnology and biopharmaceutical production. For decades, the field has relied primarily on two established expression systems namely ...

If you thought September was huge for M&As in the biopharma space, you didn’t see October coming. Nine major M&As were signed, with most of them being multi-billion-dollar deals in various therapeutic ...

Today, AAVantgarde Bio raises $141 million (€122 million) in a series B round to advance its gene therapy programs for inherited eye diseases, marking one of Europe’s largest private financings in ...

Synthetic biology (SynBio) has stopped dividing itself by categories — red, yellow, green, blue, white — medicine, environment, agriculture, water, and industry —and is now united as one movement, ...